Ultra Rapid Detoxification (UROD) — CPB 0317 | AETNA Coverage Update

Aetna reaffirmed its blanket denial of ultra rapid detoxification (UROD) under CPB 0317, effective December 18, 2025 — classifying the procedure as experimental and investigational for all indications, with no path to coverage for claims billing HCPCS J2312 or J2313.

If your billing team submits claims for UROD services to Aetna, a CVS Health company, this modification changes nothing about the outcome — but it does update the formal policy language you'll see cited on remittance advice and denial letters. Know what you're dealing with before you spend time on appeals.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Ultra Rapid Detoxification (UROD) — CPB 0317
Policy Code	CPB 0317
Change Type	Modified
Effective Date	December 18, 2025
Impact Level	High — blanket non-coverage for all UROD indications
Specialties Affected	Addiction medicine, anesthesiology, internal medicine, behavioral health
Key Action	Stop submitting UROD claims to Aetna and redirect affected patients to covered detoxification alternatives before billing

---

Aetna Ultra Rapid Detoxification Coverage Criteria and Medical Necessity Requirements 2025

The Aetna UROD coverage policy under CPB 0317 is not complicated. Aetna does not cover ultra rapid detoxification. Full stop.

Under this policy, Aetna finds that UROD fails to meet the medical necessity standard required for coverage. The payer's position is that the clinical effectiveness of UROD has not been established. That language — "effectiveness has not been established" — is the specific basis for denial, and you'll see it on every remittance.

The December 18, 2025 modification updates CPB 0317 in the Aetna system but does not open any new coverage criteria. There is no prior authorization pathway that unlocks reimbursement here. No amount of documentation gets you to a paid claim for UROD services billed to Aetna.

The Aetna ultra rapid detoxification coverage policy applies across the full range of opioid abuse and dependence diagnoses — F11.10 through F11.29 — and extends to poisoning and adverse effect codes in the T40 series. If you're billing UROD for any opioid-related diagnosis and Aetna is the payer, expect denial.

---

Aetna Ultra Rapid Detoxification Exclusions and Non-Covered Indications

UROD billing under any indication is non-covered under this policy. Aetna's classification is "experimental, investigational, or unproven" — the strongest non-coverage language in their system.

This designation means no exception process exists. It also means any appeal arguing medical necessity for UROD will fail at the payer level. Aetna's clinical policy bulletins define experimental or investigational procedures as those lacking sufficient evidence of safety and effectiveness — and that's the box CPB 0317 puts UROD in permanently, until Aetna decides otherwise.

The policy covers UROD "as a clinical detoxification treatment and for all other indications." That phrase matters. Some providers attempt to argue UROD under adjacent billing frameworks — anesthesia, sedation management, naloxone administration. This policy closes that door. Any claim where UROD is the underlying service is non-covered.

HCPCS J2312 (naloxone hydrochloride injection, 0.01 mg) and J2313 (naloxone hydrochloride [Zimhi], 0.01 mg) appear in the CPB 0317 policy as related codes. These codes can be covered in other clinical contexts — naloxone reversal of overdose, for instance. But when billed as part of a UROD protocol, Aetna will tie the claim back to this policy and deny it.

---

Coverage Indications at a Glance

---

Aetna Ultra Rapid Detoxification Billing Guidelines and Action Items 2025

The effective date of December 18, 2025 means this policy language is already active. If your team hasn't reviewed your charge capture and denial workflow for UROD, do it now.

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Ultra Rapid Detoxification Under CPB 0317

HCPCS Codes Related to CPB 0317

These codes appear in the Aetna CPB 0317 policy as related codes. Neither is covered when billed as part of a UROD protocol.

Code	Type	Description Copy
J2312	HCPCS	Injection, naloxone hydrochloride, not otherwise specified, 0.01 mg
J2313	HCPCS	Injection, naloxone hydrochloride (Zimhi), 0.01 mg

Key ICD-10-CM Diagnosis Codes Under CPB 0317

All opioid abuse, dependence, poisoning, and adverse effect codes are listed in the policy. The full range is below.

---

The Real Issue With This Policy

CPB 0317 is a blanket denial policy with no off-ramp. That's unusual to say out loud, but your billing team needs to hear it.

Most payer policies have some complexity — covered when X, not covered when Y, prior authorization required for Z. CPB 0317 has none of that. Aetna's position on UROD is total. The policy applies to UROD "as a clinical detoxification treatment and for all other indications." There is no covered indication, no exception, and no prior authorization process that changes the outcome.

The December 18, 2025 update doesn't make things worse — but it does refresh the citation Aetna will use on denials going forward. If your revenue cycle team has been treating CPB 0317 denials as standard medical necessity disputes and sending them through a normal appeal cycle, you're wasting resources. Recognize the denial type, close the claim, and fix the upstream process.

If you run a practice in addiction medicine or anesthesiology and you're actively offering UROD, you need a direct conversation with your compliance officer about patient billing and financial exposure — not just the payer reimbursement question. That conversation is more important than any billing workflow change.

---